-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

403 Self-Rated Health Is an Independent Predictor of Subsequent Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Myeloid Malignancies: A BMTSS Report

Program: Oral and Poster Abstracts
Type: Oral
Session: 908. Outcomes Research: Myeloid Malignancies: Patient Reported Outcomes and their Association with Clinical Outcomes in Patients with Myeloid Malignancies
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality)
Saturday, December 7, 2024: 4:00 PM

Nora Balas, PhD1*, Joshua Richman1*, Wendy Landier, PhD2*, Sadeep Shrestha, PhD3*, Katia J Bruxvoort, PhD3*, Lindsey Hageman, MPH1*, Qingrui Meng, MS2*, Elizabeth Ross3*, Alysia Bosworth, BA4*, Hok Sreng Te5*, F. Lennie Wong, PhD6, Ravi Bhatia, MD7, Stephen J. Forman, MD, FACP8, Saro Armenian, DO, MPH4, Daniel Weisdorf, MD5 and Smita Bhatia, MD, MPH1

1Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL
2University of Alabama At Birmingham, Birmingham, AL
3University of Alabama at Birmingham, Birmingham, AL
4City of Hope National Medical Center, Duarte, CA
5University of Minnesota, Minneapolis, MN
6City of Hope, Duarte, CA
7Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL
8Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte, CA

Background: BMT is offered with curative intent to patients with myeloid malignancies (acute myeloid leukemia [AML], myelodysplastic syndrome [MDS] and chronic myeloid leukemia [CML]). Despite the decline in early mortality due to refinement in transplantation strategies and advances in supportive care, BMT recipients carry a significant burden of late-occurring morbidity, placing them at high risk for late mortality when compared with the general population. Previous studies have identified several causes of late mortality including disease recurrence and treatment-related chronic health conditions (e.g., subsequent malignancies and cardiovascular disease). Self-rated health (SRH) is a single-item measure of an individual’s evaluation of their health status and has been reported as an independent predictor of mortality in the general population and cancer patients treated with conventional therapy. The association between SRH and subsequent all-cause and cause-specific late mortality among BMT survivors of myeloid malignancies has not been examined. Finally, sociodemographic and clinical factors associated with suboptimal SRH among BMT survivors remain unstudied.

Methods: We examined the prevalence of suboptimal SRH and its association with subsequent all-cause and cause-specific late mortality among myeloid malignancy patients treated with BMT. Study participants were drawn from BMTSS and included patients with AML, MDS or CML, who were transplanted between 1974 and 2014 at three participating sites and had survived ≥2y post-BMT. Participants (≥18y) completed a survey at a median of 10y from BMT and were followed for a median of 6y after survey completion for vital status and cause of death. Survivors provided information on sociodemographic characteristics, chronic health conditions (as diagnosed by their healthcare providers), health behaviors, and SRH (single item, rated as excellent, very good, good, fair or poor; excellent, very good or good SRH were classified as good SRH and all else as suboptimal SRH). National Death Index (NDI) Plus, Accurint database, and medical records provided vital status through December 2021. Multivariable regression analyses determined the association between SRH and all-cause mortality (Cox regression) and cause-specific mortality (recurrence-related [RRM] and non-recurrence related mortality [NRM]) (sub-distribution hazard regression) after adjusting for relevant sociodemographic, clinical variables, therapeutic exposures, post-BMT chronic health conditions and development of post-BMT relapse. Factors associated with suboptimal SRH were analyzed using multivariable logistic regression.

Results: Of the 1,276 participants (AML/MDS: n=910; CML: n=365); 86.6% allogeneic BMT; median age at BMT 42y; 50.6% males; 76.3% non-Hispanic white. Overall, 322 (25.3%) BMT survivors reported suboptimal SRH, and 267 died after survey completion (20.9%). BMT survivors who reported suboptimal SRH had a 2.1-fold increased hazard of all-cause mortality (95%CI=1.6-2.8), 1.9-fold increased hazard of RRM (95%CI:0.9-4.1), and 1.4-fold increased hazard of NRM (95%CI:0.8-2.6) compared to those who reported good SRH, after adjusting for age at survey, BMT era (1974-1989; 1990-2004; 2005-2014), sex, race/ethnicity, socioeconomic status (SES: <college and <$50,000; <college and ≥$50,000; ≥college and <$50,000; ≥college and ≥$50,000), age at BMT, BMT type/cGvHD (autologous BMT; allogeneic BMT/no cGvHD; allogeneic BMT/cGvHD), conditioning intensity/TBI, (NMA/no TBI; NMA/TBI; MAC/no TBI; MAC/TBI), post-BMT relapse, grades 3-4 chronic health conditions, psychological distress, smoking and alcohol consumption. Low socioeconomic status, pain, psychological distress, lack of exercise and severe/life threating chronic health conditions were associated with suboptimal SRH.

Conclusions: This single-item measure could serve to identify vulnerable sub-populations that could benefit from interventions to mitigate the risk for subsequent mortality.

Disclosures: Forman: Allogene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Lixte Bio: Consultancy, Membership on an entity's Board of Directors or advisory committees. Armenian: Pfizer: Research Funding.

Previous Abstract | Next Abstract >>
*signifies non-member of ASH